Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Revenue for 13 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.

• Quarterly Revenue fell 91.36% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 365.55% YoY) and the FY2025 annual result came in at $1.3 billion, up 303.5% from the prior year.
• Revenue declined to $7.4 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
• Over the last five years, Revenue for LKFT reached as high as $1.0 billion in Q4 2025 and fell as low as -$58.2 million in Q2 2024.
• A 5-year average of $124.8 million and a median of $69.6 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue tumbled 185.24% — and 2025, when it soared 7733.23%.
• Year by year, Revenue stood at $205.7 million in 2022, then slumped by 37.87% to $127.8 million in 2023, then slumped by 89.76% to $13.1 million in 2024, then surged by 7733.23% to $1.0 billion in 2025, then sank by 99.28% to $7.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $7.4 million, $1.0 billion, and $81.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.